Cargando…

Subset Analysis for Screening Drug–Drug Interaction Signal Using Pharmacovigilance Database

Many patients require multi-drug combinations, and adverse event profiles reflect not only the effects of individual drugs but also drug–drug interactions. Although there are several algorithms for detecting drug–drug interaction signals, a simple analysis model is required for early detection of ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Noguchi, Yoshihiro, Tachi, Tomoya, Teramachi, Hitomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466158/
https://www.ncbi.nlm.nih.gov/pubmed/32806518
http://dx.doi.org/10.3390/pharmaceutics12080762
_version_ 1783577748120272896
author Noguchi, Yoshihiro
Tachi, Tomoya
Teramachi, Hitomi
author_facet Noguchi, Yoshihiro
Tachi, Tomoya
Teramachi, Hitomi
author_sort Noguchi, Yoshihiro
collection PubMed
description Many patients require multi-drug combinations, and adverse event profiles reflect not only the effects of individual drugs but also drug–drug interactions. Although there are several algorithms for detecting drug–drug interaction signals, a simple analysis model is required for early detection of adverse events. Recently, there have been reports of detecting signals of drug–drug interactions using subset analysis, but appropriate detection criterion may not have been used. In this study, we presented and verified an appropriate criterion. The data source used was the Japanese Adverse Drug Event Report (JADER) database; “hypothetical” true data were generated through a combination of signals detected by three detection algorithms. The accuracy of the signal detection of the analytic model under investigation was verified using indicators used in machine learning. The newly proposed subset analysis confirmed that the signal detection was improved, compared with signal detection in the previous subset analysis, on the basis of the indicators of Accuracy (0.584 to 0.809), Precision (= Positive predictive value; PPV) (0.302 to 0.596), Specificity (0.583 to 0.878), Youden’s index (0.170 to 0.465), F-measure (0.399 to 0.592), and Negative predictive value (NPV) (0.821 to 0.874). The previous subset analysis detected many false drug–drug interaction signals. Although the newly proposed subset analysis provides slightly lower detection accuracy for drug–drug interaction signals compared to signals compared to the Ω shrinkage measure model, the criteria used in the newly subset analysis significantly reduced the amount of falsely detected signals found in the previous subset analysis.
format Online
Article
Text
id pubmed-7466158
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74661582020-09-14 Subset Analysis for Screening Drug–Drug Interaction Signal Using Pharmacovigilance Database Noguchi, Yoshihiro Tachi, Tomoya Teramachi, Hitomi Pharmaceutics Article Many patients require multi-drug combinations, and adverse event profiles reflect not only the effects of individual drugs but also drug–drug interactions. Although there are several algorithms for detecting drug–drug interaction signals, a simple analysis model is required for early detection of adverse events. Recently, there have been reports of detecting signals of drug–drug interactions using subset analysis, but appropriate detection criterion may not have been used. In this study, we presented and verified an appropriate criterion. The data source used was the Japanese Adverse Drug Event Report (JADER) database; “hypothetical” true data were generated through a combination of signals detected by three detection algorithms. The accuracy of the signal detection of the analytic model under investigation was verified using indicators used in machine learning. The newly proposed subset analysis confirmed that the signal detection was improved, compared with signal detection in the previous subset analysis, on the basis of the indicators of Accuracy (0.584 to 0.809), Precision (= Positive predictive value; PPV) (0.302 to 0.596), Specificity (0.583 to 0.878), Youden’s index (0.170 to 0.465), F-measure (0.399 to 0.592), and Negative predictive value (NPV) (0.821 to 0.874). The previous subset analysis detected many false drug–drug interaction signals. Although the newly proposed subset analysis provides slightly lower detection accuracy for drug–drug interaction signals compared to signals compared to the Ω shrinkage measure model, the criteria used in the newly subset analysis significantly reduced the amount of falsely detected signals found in the previous subset analysis. MDPI 2020-08-12 /pmc/articles/PMC7466158/ /pubmed/32806518 http://dx.doi.org/10.3390/pharmaceutics12080762 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Noguchi, Yoshihiro
Tachi, Tomoya
Teramachi, Hitomi
Subset Analysis for Screening Drug–Drug Interaction Signal Using Pharmacovigilance Database
title Subset Analysis for Screening Drug–Drug Interaction Signal Using Pharmacovigilance Database
title_full Subset Analysis for Screening Drug–Drug Interaction Signal Using Pharmacovigilance Database
title_fullStr Subset Analysis for Screening Drug–Drug Interaction Signal Using Pharmacovigilance Database
title_full_unstemmed Subset Analysis for Screening Drug–Drug Interaction Signal Using Pharmacovigilance Database
title_short Subset Analysis for Screening Drug–Drug Interaction Signal Using Pharmacovigilance Database
title_sort subset analysis for screening drug–drug interaction signal using pharmacovigilance database
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466158/
https://www.ncbi.nlm.nih.gov/pubmed/32806518
http://dx.doi.org/10.3390/pharmaceutics12080762
work_keys_str_mv AT noguchiyoshihiro subsetanalysisforscreeningdrugdruginteractionsignalusingpharmacovigilancedatabase
AT tachitomoya subsetanalysisforscreeningdrugdruginteractionsignalusingpharmacovigilancedatabase
AT teramachihitomi subsetanalysisforscreeningdrugdruginteractionsignalusingpharmacovigilancedatabase